Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid

• Status: Recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The clinical trial was designed to prove that Arsenic plus ATRA possibly had an effect on improving the symptoms, reducing the early mortality rate and prolonging the total survival time of patients with newly diagnosed or relapsed AML.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: First Affiliated Hospital Xi'an Jiaotong University
• Treatments: Arsenic Trioxide; Tretinoin

Criteria

Inclusion Criteria:

• Newly diagnosed or relapsed AML.Diagnosis based on Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia(not APL)(2018)

• Older than 18 years old

• Patients or their families signed written informed consent

Exclusion Criteria:

• Be allergic to the drug ingredient, the supplementary material or the allergic constitution person

• Cardiac insufficiency, renal insufficiency, significant arrhythmias, EKG abnormalities or other important organ dysfunction

• Combined with other malignant tumors

• Pregnant and lactating women

• Participants in other drug trials in the last 3 months

• Suffering from mental illness or other circumstances which unable to carry out the plan

• Other patients who were not suitable for the study